BioCentury | Dec 1, 2020
Product Development

Nov. 30 Quick Takes: Grail piloting blood test in U.K.; plus Rhythm, Kadmon, venture rounds for Adrenomed, Xbiome, Transition

...agonist next quarter.May PDUFA date for Kadmon’s belumosudilFDA granted priority review to belumosudil (KD025) from Kadmon...
...NASDAQ:KDMN) to treat chronic graft-versus-host disease (GvHD). The ROCK2 inhibitor’s PDUFA date is May 30. In May, Kadmon...
...and 74%, respectively, in the pivotal Phase II open-label ROCKstar study for third-line chronic GvHD. Kadmon...
BioCentury | Nov 30, 2020
Management Tracks

New CMO and Takeda alum Palmer adds to Ascletis’ push into NASH

...as its first CMO.Palmer held a senior post at Shire plc, which Takeda acquired, and Kadmon...
BioCentury | May 22, 2020
Product Development

May 21 Quick Takes: EC approves Zolgensma for SMA; plus Sunovion, Kadmon, Sorrento, tafasitamab, Zentalis’ new JV

...oral films containing apomorphine from Aquestive Therapeutics Inc. (NASDAQ:AQST). Kadmon’s GvHD therapy heading for FDA Kadmon...
...of motor neuron 1 telomeric SMN2 - Survival of motor neuron 2 centromeric Robin Sawka, BioCentury Staff Kadmon...
BioCentury | Nov 15, 2019
Financial News

Despite flurry of deals, follow-ons well short of 2018’s total

...gained $15.96 to $203.44 Thursday. Also raising capital on the back of positive data was Kadmon...
...after proposing the offering at a 5% discount to its close that day. On Monday, Kadmon...
...chronic graft-versus-host disease (see “Early Success in GvHD sets up NDA for Kadmon’s Lead” ). Kadmon’s...
BioCentury | Nov 12, 2019
Clinical News

Early success in GvHD sets up NDA for Kadmon’s lead

...primary endpoint at an interim analysis of a pivotal trial for third-line chronic graft-versus-host disease, Kadmon...
...NDA next year for KD025 following next half's primary analysis. On a conference call Monday, Kadmon...
...Because the interim analysis covers all the trial's patients, the best ORR will not decrease. Kadmon...
BioCentury | Oct 25, 2019
Company News

Management tracks: Akouos, Kronos and Noveome

...SVP of operations. He was VP of CMC at the Kadmon Pharmaceuticals LLC subsidiary of Kadmon...
BioCentury | May 29, 2019
Company News

CHMP against Emmaus' sickle cell therapy, Taiwan Liposome's doxorubicin

...and free radical scavenger is approved in the U.S. The committee backed approval of Cufence trientine...
...edaravone (MCI-186, radicava) Syprine, trientine hydrochloride Emmaus Life Sciences Inc. Mitsubishi Tanabe Pharma Corp. Novartis AG Taiwan Liposome Co. Ltd. Cufence trientine...
BioCentury | Dec 28, 2018
Company News

Management tracks: Schwartz steps down as Kadmon chairman

Kadmon Holdings Inc. (NYSE:KDMN) said Bart Schwartz is stepping down as chairman, citing Schwartz’s increasing responsibilities at his charitable commitments. The inflammatory and fibrotic disease company is seeking a successor. CytoDyn Inc. (OTCBB:CYDY) hired Nitya...
BioCentury | Jun 15, 2018
Financial News

Ahead of new trials, Kadmon raises $100M

...Kadmon's close of $3.35 on June 11, before it proposed the offering after market hours. Kadmon's...
...chronic graft-versus-host disease (GvHD), idiopathic pulmonary fibrosis (IPF) and moderate to severe psoriasis. Next quarter, Kadmon...
...in the U.S. to treat chronic GvHD. Kadmon Holdings Inc. (NYSE:KDMN), New York, N.Y. Allison Johnson KD025, slx-2119 Kadmon...
BioCentury | Jun 15, 2018
Financial News

MeiraGTx trades flat after $75M IPO

...the xerostomia program has the same designation from FDA. MeiraGTx launched in 2015 out of Kadmon...
Items per page:
1 - 10 of 92